Nuclear Neurology

Sang Eun Kim

doi:10.5124/jkma.2003.46.3.175

J Korean Med Assoc > Volume 46(3); 2003 > Article

Kim: Nuclear Neurology

Special Issue

Recent Advances in Nuclear Medicine

Journal of the Korean Medical Association

Journal of the Korean Medical Association 2003; 46(3): 175-179.

Published online: March 31, 2003

DOI: http://dx.doi.org/10.5124/jkma.2003.46.3.175

Nuclear Neurology

Sang Eun Kim, M.D.

Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea. sekim@smc.samsung.co.kr

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Functional brain imaging with single photon emission computed tomography (SPECT) and positron emission tomography (PET) enables the in vivo study of specific neurochemical processes in the context of normal regulatory mechanisms and pathophysiological alterations of the brain. Receptor studies with SPECT and PET have focused on the occupancy during drug treatment, quantification in neuropsychiatric diseases and visualization of specific pathology. SPECT and PET imaging of dopamine transporters can play an important role in detecting neuronal degeneration in parkinsonian syndromes and in drug-induced neurotoxicity. This article summarizes the SPECT and PET studies to evaluate the dopaminergic system in the human brain and their clinical applications.

SPECT; PET; Dopamine

References

1. Wagner HN Jr, Burns HD, Dannals RF, Wong DF, Langstrom B, Kuhar MJ, et al. Imaging dopamine receptors in the human brain by positron tomography. Science 1983;221:1264-1266.

2. Garnett ES, Firnau G, Nahmias C. Dopamine visualized on the basal ganglia of living man. Nature 1983;305:137-138.

3. Brooks DJ. Functional imaging in relation to parkinsonian syndromes. J Neurol Sci 1993;115:1-17.

7. Ring HA. The value of positron emission tomography in psychopharmacology. Hum Psychopharmacol 1995;10:79-87.

8. Kim SE, Conley RR, Tamminga CA, Chan B, Ravert HT, Wong DF, et al. Serotonin-2 receptor occupancy in schizophrenic patients treated with clozapine as measured by positron emission tomography using C-11 NMSP. J Nucl Med 1994;35:74.

9. Farde LO, Wiesel F-A, Halldin C, Sedvall G. Central D₂-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988;45:71-76.

Nuclear Neurology

Abstract

References

Figure 1

Figure 2

Figure 3

Table 1